2024
Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program
King B, Soung J, Tziotzios C, Rudnicka L, Joly P, Gooderham M, Sinclair R, Mesinkovska N, Paul C, Gong Y, Anway S, Tran H, Wolk R, Zwillich S, Lejeune A. Integrated Safety Analysis of Ritlecitinib, an Oral JAK3/TEC Family Kinase Inhibitor, for the Treatment of Alopecia Areata from the ALLEGRO Clinical Trial Program. American Journal Of Clinical Dermatology 2024, 25: 299-314. PMID: 38263353, PMCID: PMC10867086, DOI: 10.1007/s40257-024-00846-3.Peer-Reviewed Original ResearchConceptsAdverse eventsAlopecia areataIncidence rateKinase inhibitorsTreatment of alopecia areataPlacebo-controlled cohortAdverse cardiovascular eventsClinical trial programIntegrated safety analysisOpportunistic infectionsPlacebo groupPlacebo-controlledLaboratory abnormalitiesHerpes zosterSafety profileSevere acute respiratory syndrome coronavirus 2Acute respiratory syndrome coronavirus 2Cardiovascular eventsRespiratory syndrome coronavirus 2RitlecitinibObjectiveThe objectivePhase 2aTrial programPatientsMethodsTwo cohorts
2020
Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19
Peterson D, Damsky W, King B. Reply: Calm before the storm: Understanding the role of Janus kinase inhibitors in COVID-19. Journal Of The American Academy Of Dermatology 2020, 83: e67-e68. PMID: 32344070, PMCID: PMC7194643, DOI: 10.1016/j.jaad.2020.04.097.Peer-Reviewed Original ResearchThe use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
Peterson D, Damsky W, King B. The use of Janus kinase inhibitors in the time of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Journal Of The American Academy Of Dermatology 2020, 82: e223-e226. PMID: 32278797, PMCID: PMC7144601, DOI: 10.1016/j.jaad.2020.03.099.Peer-Reviewed Original ResearchMeSH KeywordsArthritis, RheumatoidAzetidinesBetacoronavirusColitis, UlcerativeCoronavirus InfectionsCOVID-19CytokinesDermatitis, AtopicHeterocyclic Compounds, 3-RingHumansImmunomodulationJanus KinasesNitrilesPandemicsPiperidinesPneumonia, ViralPrimary MyelofibrosisPurinesPyrazolesPyrimidinesPyrrolesRandomized Controlled Trials as TopicSARS-CoV-2STAT Transcription FactorsSulfonamides